EGFR and non-small cell lung carcinoma: In conclusion, this study indicated that the combination of 1G EGFR-TKIs with chemotherapy or afatinib monotherapy was associated with a favorable response and promising PFS benefit for NSCLC patients with uncommon EGFR alterations.